mAbxience | About us


mAbxience is a biotechnology company specialized in the research, development and manufacture of biosimilar monoclonal antibodies, part to the pharmaceutical Insud Pharma Group. Set up in 2009, it currently has two facilities for development and production, in Spain and Argentina. In December 2014, it launched its first biosimilar, rituximab, which is now approved and distributed in many markets globally. Its second product, bevacizumab, was launched in its first market in November 2016.

In mAbxience we develop the highest quality biosimilars through our state-of-the-art development and analytical platform.

Our work methodology is our identity.

A methodology that guides us in each of our decisions, focused on quality and efficacy:

  • Developing biosimilars adhering to a strict “quality by design” standard.

Insud Pharma, founded in 1977, makes an enormous contribution to public health around the world through the medicines, and active pharmaceutical ingredients that it develops and manufactures. With over 6000 employees based in over 40 countries, Insud Pharma is a significant and respected enterprise in the pharmaceutical and healthcare sector.

mAbxience is a fully integrated biopharmaceutical company specialized in research, development and manufacturing of biosimilars for the treatment and/or prevention of several diseases in diverse therapeutic areas.